The new kid on the block: RET in lung cancer

Cancer Discov. 2013 Jun;3(6):604-6. doi: 10.1158/2159-8290.CD-13-0174.

Abstract

RET has recently been identified as a potential new oncogenic driver in a subset of patients with non-small cell lung cancer (NSCLC). In this issue of Cancer Discovery, Drilon and colleagues report preliminary trial data with a RET inhibitor in RET fusion-positive NSCLC, validating RET as a therapeutic target in lung cancer.

Publication types

  • Comment

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma of Lung
  • Anilides / therapeutic use*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Proto-Oncogene Proteins c-ret / biosynthesis*
  • Pyridines / therapeutic use*

Substances

  • Anilides
  • Pyridines
  • cabozantinib
  • Proto-Oncogene Proteins c-ret
  • RET protein, human